首页|期刊导航|Cancer Innovation|A Novel Sensitive Technique to Detect ESR1 Hotspot Mutations in Liquid Biopsy Using Switch-Blocker-Enhanced Targeted Amplification Coupled With Pyrosequencing

A Novel Sensitive Technique to Detect ESR1 Hotspot Mutations in Liquid Biopsy Using Switch-Blocker-Enhanced Targeted Amplification Coupled With PyrosequencingOA

中文摘要

Background:The detection of estrogen receptor 1(ESR1)ligand-binding domain mutations in circulating tumor DNA(ctDNA)is crucial for guiding therapy in estrogen receptor-positive metastatic breast cancer.However,widespread clinical adoption of approaches for monitoring drug resistance and guiding treatment decisions is hindered by limitations of current methods regarding sensitivity,cost,and multiplexing capability.Methods:The application of switch-blocker technology,which has been patented for detecting ESR1 hotspot mutations(Y537S/C,D538G,E380Q,and L536H/P),suppresses the amplification of wild-type alleles while allowing specific amplification of low-frequency mutant alleles.We used a switch-blocker to inhibit the amplification of a DNA target approximately 10 base pairs in length(e.g.,the switch-blocker covering codon 536 of ESR1 targets various variants at positions 536,537,and 538).Targeted enrichment was achieved by quantitative polymerase chain reaction,followed by pyrosequencing to confirm mutation components.Next-generation sequencing and Sanger sequencing served as supplementary methods for the verification of results.Results:The ESR1-targeted DNA assay was validated for feasibility on plasmid circular templates and ctDNA linear templates.In tests using gradient-diluted ESR1 plasmid templates,the proportion of L536H mutant copies increased from 0.0015%to 16.89%after targeted amplification,while the proportion of E380Q mutant copies increased from 0.0015%to 1.35%.In ctDNA samples previously analyzed by next-generation sequencing,the switch-blocker considerably enriched other mutant copies within the coverage range of the switch element.

Yantong Zhou;Wenna Wang;Bo Lan;Chunxiao Li;Jinsong Wang;Ting Wang;Fangzhou Sun;Yan Wang;Haili Qian;Fei Ma

State Key Laboratory of Molecular Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing,ChinaDepartment of Medical Oncology,National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing,ChinaDepartment of Medical Oncology,National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing,ChinaMcKusick-Zhang Center for Genetic Medicine,Institute of Basic Medical Sciences&School of Basic Medicine,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing,ChinaState Key Laboratory of Molecular Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing,ChinaDepartment of Medical Oncology,National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing,ChinaState Key Laboratory of Molecular Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing,ChinaState Key Laboratory of Molecular Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing,ChinaState Key Laboratory of Molecular Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing,ChinaDepartment of Medical Oncology,National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing,China

医药卫生

breast cancerendocrine therapy resistanceESR1 mutationliquid biopsyPCR amplificationpyrosequencingswitch-blocker

《Cancer Innovation》 2026 (2)

P.101-112,12

The Noncommunicable Chronic Diseases-National Science and Technology Major Project,Grant/Award Number:2023ZD0502200National Natural Science Foundation of China,Grant/Award Numbers:92459304,82230058,82303912,82403982National High Level Hospital Clinical Research Funding,Grant/Award Number:2025-LYZX-D-A02CAMS Innovation Fund for Medical Sciences,Grant/Award Numbers:2025-I2M-TS-02,2025-I2M-KJ-006。

10.1002/cai2.70054

评论